MicroRNAs and JAK/STAT3 signaling: A new promising therapeutic axis in blood cancers.

Autor:	Sajjadi-Dokht M; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran., Merza Mohamad TA; Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil 44001, Iraq., Sulaiman Rahman H; Department of Physiology, College of Medicine, University of Sulaymaniyah, Sulaymaniyah 46001, Iraq.; Department of Medical Laboratory Sciences, Komar University of Science and Technology, Sulaymaniyah 46002, Iraq., Suliman Maashi M; Stem Cells and Regenerative Medicine Unit at King Fahad Medical Research Centre, Jeddah 21589, Saudi Arabia., Danshina S; Department of Propaedeutics of Dental Diseases, I. M. Sechenov First Moscow State Medical University, Moscow 119991, Russia., Shomali N; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran.; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran., Solali S; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran.; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran., Marofi F; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran.; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran., Zeinalzadeh E; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran.; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran., Akbari M; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran., Adili A; Department of Oncology, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran., Aslaminabad R; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran., Farshdousti Hagh M; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran.; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran., Jarahian M; German Cancer Research Center (DKFZ), Toxicology and Chemotherapy Unit (G401), Heidelberg 69120, Germany.
Jazyk:	angličtina
Zdroj:	Genes & diseases [Genes Dis] 2021 Dec 03; Vol. 9 (4), pp. 849-867. Date of Electronic Publication: 2021 Dec 03 (Print Publication: 2022).
DOI:	10.1016/j.gendis.2021.10.009
Abstrakt:	Blood disorders include a wide spectrum of blood-associated malignancies resulting from inherited or acquired defects. The ineffectiveness of existing therapies against blood disorders arises from different reasons, one of which is drug resistance, so different types of leukemia may show different responses to treatment. Leukemia occurs for a variety of genetic and acquired reasons, leading to uncontrolled proliferation in one or more cell lines. Regarding the genetic defects, oncogene signal transducer and activator of transcription (STAT) family transcription factor, especially STAT3, play an essential role in hematological disorders onset and progress upon mutations, dysfunction, or hyperactivity. Besides, microRNAs, as biological molecules, has been shown to play a dual role in either tumorigenesis and tumor suppression in various cancers. Besides, a strong association between STAT3 and miRNA has been reported. For example, miRNAs can regulate STAT3 via targeting its upstream mediators such as IL6, IL9, and JAKs or directly binding to the STAT3 gene. On the other hand, STAT3 can regulate miRNAs. In this review study, we aimed to determine the role of either microRNAs and STAT3 along with their effect on one another's activity and function in hematological malignancies. Competing Interests: Authors declare no conflict of interests. (© 2021 Chongqing Medical University. Production and hosting by Elsevier B.V.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu